[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Carroll Patrick Harrison, Chief Medical Officer and a director of Hims & Hers Health, Inc. (HIMS), reported the sale of 60,000 shares of Class A common stock on 08/06/2025 at a weighted average price of $53.5813 per share (sales ranged from $53.19 to $53.97). After the sale his direct beneficial ownership of Class A shares is reported as 169,940 shares.

The filing also discloses a grant of 3,656 Restricted Stock Units (RSUs) that each convert into one share of Class A common stock subject to continuous service; the RSUs vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026. The filer represents the sale price as an average weighted price and offers to provide further allocation details upon request.

Positive

• Transparent disclosure of sale price range and weighted average ($53.19–$53.97; weighted avg $53.5813)
• Clear RSU grant with explicit vesting conditions (earlier of 2026 annual meeting or June 15, 2026)

Negative

• Insider sold 60,000 Class A shares, reducing direct holdings to 169,940 shares
• Grant of 3,656 RSUs implies potential future share issuance upon vesting

Insights

Corporate Governance Expert

TL;DR: Routine executive sale with concurrent RSU grant; disclosure is complete on price range and vesting, suggesting standard compensation and liquidity activity.

The report documents a voluntary disposition of 60,000 Class A shares with a clear weighted average sale price and an explicit price range, which supports transparent disclosure practices. The subsequent reported direct ownership of 169,940 shares and the separate grant of 3,656 RSUs with a specified vesting trigger indicate standard executive compensation mechanics rather than an unexplained departure or emergency liquidity event. Impactful? Not materially impactful to company fundamentals based on the filing alone.

Securities Analyst

TL;DR: Insider sale reduces direct holdings but the RSU grant creates potential future share issuance; both are precisely documented in the filing.

From an investor disclosure perspective, the filing supplies the key figures: 60,000 shares sold at a weighted average of $53.5813 (range $53.19–$53.97) and 3,656 RSUs granted that will convert to shares upon vesting. The numbers permit simple pre- and post-transaction ownership reconciliation. Without additional context on total outstanding shares or company-wide dilution, this transaction appears routine and informational rather than materially market-moving.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carroll Patrick Harrison

(Last) (First) (Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO CA 94123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/06/2025		S		60,000	D	$53.5813(1)	169,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	08/06/2025		A		3,656		(2)	(2)	Class A Common Stock	3,656	$0	3,656	D

Explanation of Responses:

1. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $53.19 - $53.97. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

2. The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026.

Remarks:

	/s/ Alexandra Cotter Wilkins, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did HIMS report in this Form 4?

The filing reports that Carroll Patrick Harrison sold 60,000 Class A shares and was granted 3,656 RSUs.

At what price were the 60,000 shares sold (HIMS)?

The shares were sold at a weighted average price of $53.5813; reported sale prices ranged from $53.19 to $53.97.

How many HIMS shares does Carroll Harrison own after the transaction?

Following the reported sale, Carroll Harrison beneficially owns 169,940 Class A shares (direct).

What are the terms of the RSU grant reported for HIMS?

The grant is for 3,656 RSUs, each convertible into one Class A share, vesting on the earlier of the 2026 annual meeting or June 15, 2026, subject to continuous service.

Who signed or submitted the Form 4 for this HIMS filing?

The form is signed by Alexandra Cotter Wilkins, Attorney-in-Fact on behalf of the reporting person.